Mesenchymal-epithelial transition factor (MET) Kinase Inhibitor Market

• The MET Kinase inhibitors Market Size is anticipated to grow with a significant CAGR durin gthe study period (2020-2034).
• MET Kinase inhibitors are pivotal in treating non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition exon 14 skipping alterations, colorectal cancer, gastric cancer, hepatobiliary cancer, and other solid tumors.
• In 2024, the US accounted for the maximum share of the total market of c-MET in the 7MM.
• Small-molecule c-MET kinase inhibitors represent a distinct class of anticancer agents designed to selectively disrupt the interaction between the c-MET transmembrane receptor and its ligand, hepatocyte growth factor (HGF), thereby inhibiting downstream oncogenic signaling.
• Aberrant MET expression is prevalent across multiple cancer types, with dysregulated c-MET signaling linked to tumorigenesis and metastatic progression. Elevated c-MET levels are further associated with poor clinical outcomes and resistance to targeted therapies.
• HAIYITAN’s recent approval by the PMDA positions it as a significant player in Japan’s growing c-MET inhibitor market. Its regulatory success enhances credibility and sets the stage for rapid adoption in treating cancers with c-MET alterations, particularly in a market where precision oncology is expanding.
• MET overexpression and gene fusions represent potential therapeutic targets; however, the clinical relevance of MET overexpression remains uncertain. Inconsistent responses to MET-targeted therapies may stem from difficulties in distinguishing baseline from elevated expression levels, and from the fact that overexpression does not necessarily indicate MET-dependent pathway activation.
• Several companies, including Exelixis, Novartis, Incyte, AbbVie, Merck, Apollomics, Taiho Pharmaceutical, Regeneron Pharmaceuticals, Mythic Therapeutics, HUTCHMED, Janssen, and AstraZeneca, are engaged in the development of MET Kinase inhibitors with a range of approved and emerging drugs.
• TABRECTA (capmatinib) and TEPMETKO (tepotinib), two FDA-approved and highly specific small-molecule inhibitors of c-MET exon 14 skipping mutations, are new and important therapeutic options for the treatment of NSCLC patients harboring c-MET alterations. TABRECTA is expected to continue its market-leading position in c-MET NSCLC thanks to its first-to-market advantage.
• TABRECTA is anticipated to generate ~USD 388 million in the 7MM by 2034. Novartis has removed TABRECTA from the market in Germany due to "issues" with the AMNOG system. In February, the Federal Joint Committee (G-BA) voted that the added benefit of TABRECTA was "not proven" for treating advanced NSCLC with specific genetic mutations.

DelveInsight’s “Mesenchymal-epithelial transition factor (MET) Kinase Inhibitor Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the MET kinase inhibitor, historical and Competitive Landscape as well as the MET Kinase inhibitor therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The MET Kinase inhibitor market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM MET Kinase Inhibitor market size from 2020 to 2034. The report also covers current MET Kinase Inhibitor treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

MET Kinase Inhibitor Disease Understanding and Treatment Algorithm

MET Kinase Inhibitor Overview

Mesenchymal epithelial transition (MET) tyrosine kinase inhibitors are drugs used for treating lung cancer. MET tyrosine kinase is a receptor present on the surface of various cells. These receptors have a ligand called hepatocyte growth factor (HGF). The binding of hepatocyte growth factor to mesenchymal-epithelial transition receptors leads to cell formation and wound healing in normal cells. However, mutations of mesenchymal-epithelial transition can lead to the overactivity of cells, leading to tumor development. MET tyrosine kinase inhibitors bind to mesenchymal-epithelial transition and prevent the binding of hepatocyte growth factor, thereby causing tumor cell death. 

MET tyrosine kinase inhibitors are used to treat NSCLC in adults. MET proto-oncogene alterations are known driver oncogenes in NSCLC. Since the identification of mesenchymal-epithelial transition as a potential therapeutic target, extensive clinical trials have been performed. As a result, MET-targeted therapies, including MET tyrosine kinase inhibitors, monoclonal antibodies, and MET antibody-drug conjugates now play important roles in the standard treatment of MET-altered NSCLC; they have considerably improved the outcomes of patients with tumors that harbor MET oncogenic drivers. 

Further details related to country-based variations are provided in the report…

Mesenchymal-epithelial transition factor (MET) Kinase Inhibitor Epidemiology

The MET Kinase inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total incident cases of selected indication for MET Kinase inhibitor, total eligible patient pool for MET Kinase inhibitor in selected indication, total treated cases in selected indication for MET Kinase inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034. 

MET Kinase Inhibitor Drug Analysis

The drug chapter segment of the MET Kinase inhibitor reports encloses a detailed analysis of MET Kinase inhibitor-marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the MET Kinase inhibitor’s clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

MET Kinase Inhibitor Marketed Drugs

TEPMETKO (tepotinib): Merck

TEPMETKO is used to treat adults with lung cancer that has spread to other parts of the body or cannot be removed by surgery. The medicine is given, when the cancer cells have an alteration in the mesenchymal-epithelial transition gene and previous treatment has not helped to stop the disease. An alteration in the mesenchymal-epithelial transition gene can lead to the production of an abnormal protein, which can then cause uncontrolled cell growth and cancer. The US FDA granted breakthrough therapy designation (BTD) and orphan drug designation (ODD) for tepotinib. Initially approved by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in 2020, TEPMETKO subsequently received accelerated approval from the FDA in 2021 and gained approval from the European Commission in 2022. Notably, in February 2024, the FDA granted regular approval for TEPMETKO specifically for metastatic NSCLC harboring MET exon 14 skipping alterations.

TABRECTA (capmatinib): Novartis/Incyte

TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. In August 2022, TABRECTA received standard approval from the FDA, having initially obtained accelerated approval in 2020. In 2020, the FDA granted BTD and ODD to TABRECTA. Incyte projects 2032 as the anticipated year for minimum market exclusivity for TABRECTA.

Note: Detailed current therapies assessment will be provided in the full report of MET Kinase inhibitor.

MET Kinase Inhibitor Emerging Drugs

ORPATHYS + TAGRISSO: AstraZeneca/HUTCHMED

ORPATHYS is an oral, potent, and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification, or protein overexpression. The current standard of care for patients with EGFR-mutated lung cancer who progress on targeted treatment is chemotherapy. 

The results from SAVANNAH suggest that ORPATHYS added to TAGRISSO during disease progression could provide these biomarker-selected patients with a potentially less toxic, more effective treatment option. The global SAFFRON Phase III trial will further assess the TAGRISSO plus ORPATHYS combination versus platinum-based doublet chemotherapy in patients with EGFRm, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC following TAGRISSO. 

• In March 2025, AstraZeneca announced presentation of new study results from the SAVANNAH Phase II trial at the European Lung Cancer Congress (ELCC) 2025. The global SAFFRON Phase III trial will further assess the TAGRISSO plus ORPATHYS combination versus platinum-based doublet chemotherapy in patients with EGFRm, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC following treatment with TAGRISSO.
• In October 2024, HUTCHMED announced positive high-level results from the SAVANNAH Phase II trial that showed TAGRISSO plus ORPATHYS demonstrated a high, clinically meaningful and durable objective response rate (ORR) for patients with EGFRm NSCLC with high levels of MET overexpression and/or amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on treatment with TAGRISSO.
• In January 2023, the US FDA granted FTD to ORPATHYS + TAGRISSO for patients with EGFRm NSCLC with high levels of MET overexpression and/or amplification.

Vebreltinib (APL-101): Apollomics

Vebreltinib is a novel small molecule kinase inhibitor that targets c-MET. It is a Type 1b class highly selective c-MET inhibitor. Vebreltinib has demonstrated strong tumor inhibitory effect in a variety of preclinical c-MET dysregulated human gastric, hepatic, pancreatic and lung cancer xenograft animal models and patient-derived xenograft models (PDX). Apollomics announced a strategic prioritization for the treatment of NSCLC patients with MET Amplification.

• In March 2025, Apollomics and LaunXP announced a collaboration agreement for the exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of NSCLC. Under the terms of the agreement, Apollomics is to receive upfront payments totaling USD 10 million within 60 days of the date of the agreement.
• In August 2024, Apollomics announced interim data from its SPARTA Phase II clinical trial for non-CNS MET fusion solid tumors. Apollomics also announced results from interim analysis of 38 patients in the SPARTA MET amplification cohorts.
• In March 2024, Apollomics announced an updated efficacy analysis by GCN subgroup in the treatment of NSCLC patients with MET Exon 14 skipping mutations.

Note: Detailed emerging therapy assessment will be provided in the final report...

MET Kinase Inhibitor Market Outlook 

The market for MET Kinase inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of MET Kinase inhibitors, and the increasing number of MET Kinase inhibitors that are under clinical trials and filed for approval by various companies. 

MET, an oncogene, has been evaluated for many histologists, including NSCLC. Traditionally, when investigators looked at MET as a driver, they primarily looked at gene amplifications. There is a small population of patients who do have an amplification of the MET gene. In addition, there were reports several years ago that drugs effectively targeting MET could potentially be effective approaches in such cases. However, more recently, there has been a recognition that a significant percentage of patients with NSCLC have a mutation. A host of different mutations led to the same consequence, which is the skipping of MET exon 14 in the eventual product of MET. This leads to a decreased ability for MET to be destroyed, and that has more recently been recognized as a vital driver mutation in approximately 3–4% of patients with NSCLC. Several MET TKIs (TABRECTA and TEPMETKO) are currently approved globally for treating METex14+ NSCLC. The only MET inhibitor approved in China is savolitinib. 

Several key players, including Merck, Novartis, Haihe Biopharma, Taiho Pharmaceutical, AbbVie, AstraZeneca, HUTCHMED, Apollomics, Regeneron Pharmaceuticals, Mythic Therapeutics, and others, are involved in developing drugs for MET Kinase inhibitors for various indications such as NSCLC, renal cell carcinoma, thyroid cancer, and others. Overall, this is an exciting new class of agents with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of MET Kinase inhibitors and define their role in the therapy of cancer.

MET Kinase Inhibitor Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging MET Kinase inhibitors expected to be launched in the market during 2025–2034.

MET Kinase Inhibitor Pipeline Development Activities

The MET Kinase Inhibitor pipeline report provides insights into different MET Kinase Inhibitor clinical trials Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics. 

The presence of numerous drugs under different stages is expected to generate immense opportunity for MET Kinase inhibitors market growth over the forecast period.

MET Kinase Inhibitor Pipeline Development Activities

The MET Kinase Inhibitor clinical trials analysis report covers information on collaborations, acquisitions and mergers, licensing, and patent details for MET Kinase inhibitor therapies. 

KOL Views on MET Kinase Inhibitor

To keep up with current and future market trends, we take Industry Experts’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on MET Kinase inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Texas, Dana-Farber Cancer Institute, Kanazawa University, MD Anderson Cancer Center, the Memorial Sloan Kettering Cancer Center, and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or MET Kinase inhibitor market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

MET Kinase Inhibitor Report Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. 

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. 

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

MET Kinase Inhibitor Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. 

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Key MET Kinase Inhibitor Updates

• In June 2025, HUTCHMED announced primary results from the interim analysis of the SACHI Phase III study. These results were presented in a late-breaking oral presentation at ASCO 2025.
• In May 2025, US FDA approved EMRELIS (telisotuzumab vedotin-tllv) for adults with previously treated advanced NSCLC with High c-MET protein overexpression.
• In April 2025, Apollomics announced new interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and NSCLC with MET amplification.

Scope of the MET Kinase Inhibitor Market Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of the MET Kinase inhibitor, explaining its mechanism, and therapies (current and emerging).
• Comprehensive insight into the Competitive Landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the MET Kinase inhibitor market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM MET Kinase inhibitor market.

MET Kinase Inhibitor Market Report Insights

• MET Kinase Inhibitor Targeted Patient Pool
• MET Kinase Inhibitor Therapeutic Approaches
• MET Kinase Inhibitor Pipeline Analysis
• MET Kinase Inhibitor Market Size and Trends
• Existing and Future Market Opportunity

MET Kinase Inhibitor Market Report Key Strengths

• Ten Year Forecast
• The 7MM Coverage 
• Key Cross Competition 
• MET Kinase Inhibitor Drugs Uptake
• Key MET Kinase Inhibitor Market Forecast Assumptions

MET Kinase Inhibitor Market Report Assessment

• Current MET Kinase Inhibitor Treatment Practices
• MET Kinase Inhibitor Unmet Needs
• MET Kinase Inhibitor Pipeline Product Profiles
• MET Kinase Inhibitor Market Attractiveness
• Qualitative Analysis (SWOT)
• MET Kinase Inhibitor Market Drivers
• MET Kinase Inhibitor Market Barriers

Key Questions Answered In The MET Kinase Inhibitor Market Report:

• What was the MET Kinase inhibitor total market size, the market size by therapies, market share (%) distribution, and what would it look like in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for MET Kinase inhibitors?
• What are the pricing variations among different geographies for approved therapies?
• How has the reimbursement landscape for MET Kinase inhibitors evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with MET Kinase inhibitors? What will be the growth opportunities across the 7MM for the patient population of MET Kinase inhibitors?
• What are the key factors hampering the growth of the MET Kinase inhibitor market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for MET Kinase inhibitors?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to buy MET Kinase Inhibitor Market Forecast Report

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the MET Kinase inhibitor Market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.